Core Viewpoint - The company, Jianxin Co., Ltd. (300107.SZ), is expected to report a net loss attributable to shareholders ranging from -29 million to -20 million yuan for 2025, with a net loss of -31 million to -22 million yuan after excluding non-recurring gains and losses [1] Group 1: Financial Performance - The company is experiencing losses due to short-term operational pressures and the need to balance long-term strategic planning [1] - Sales of key products, including dye intermediates, paper chemicals, and pharmaceutical and agricultural intermediates, have decreased compared to the previous year, influenced by weak industry demand and intensified market competition [1] - The prices of major products have also declined to varying degrees compared to last year, leading to a decrease in profit margins [1] Group 2: R&D and Strategic Initiatives - Increased investment in new product development and upgrades to existing products has raised R&D expenses, negatively impacting current profits [1] - The company views the current performance fluctuations as a short-term phenomenon, with R&D investments gradually converting into technological reserves for future product upgrades and market expansion [1] - Future strategies include optimizing operational strategies, accurately seizing market opportunities, leveraging technological advantages to capture market share in niche segments, and implementing reforms to reduce costs and enhance efficiency [1]

Core Viewpoint - The company expects a negative net profit for the fiscal year 2025, with a projected net profit attributable to shareholders ranging from -29 million to -20 million yuan, and a net profit after deducting non-recurring gains and losses estimated between -31 million and -22 million yuan [1] Group 1: Financial Performance - The company reported a loss in performance during the reporting period, primarily due to short-term operational pressures and the need to balance long-term strategic planning [1] - The decline in sales volume for products such as dye intermediates, paper chemicals, and pharmaceutical and agricultural intermediates is attributed to weak industry demand and intensified market competition [1] - The prices of major products have decreased to varying degrees compared to the previous year, leading to a decline in profit margins [1] Group 2: Investment and R&D - Increased investment in new product development and upgrades to existing products has resulted in higher R&D expenses, negatively impacting current profits [1]